·Chinese(gb) ·English ·ฉบับภาษาไทย ·Tiếng Việt
WAPWeb Accessibility RSS
Home About Liuzhou Government Liuzhou News Live in Liuzhou Travel in Liuzhou Invest in Liuzhou Interact
Current Location:  Home > Liuzhou News > China
 
China's homegrown anti-cancer drug wins international recognition
 
Date:2019-01-10  Source:Xinhua
 China's homegrown drug Sintilimab designed for treating relapsed or refractory classic Hodgkin lymphoma has won international recognition, with its clinical trial research published as the cover paper in the January issue of The Lancet Haematology.

Hodgkin lymphoma is a rare malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although the cure rate of early treatment is high, patients have a 20 percent chance of recurrence after their first treatment. Patients with relapsed or refractory classic Hodgkin lymphoma lack effective treatment in China.

Sintilimab, an anti-PD-1 drug, is a kind of checkpoint inhibitor, an emerging anti-cancer therapeutic modality that boosts the immune system to help the body target and kill tumors.

Professor Shi Yuankai from the Cancer Hospital, Chinese Academy of Medical Sciences, led the clinical research, which enrolled 96 patients with relapsed or refractory classic Hodgkin's lymphoma from 18 hospitals in China.

Results showed that Sintilimab has favorable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma, with 80.4 percent of the patients showing an objective response.

Stephen M Ansell from the Division of Hematology at the Mayo Clinic commented that Sintilimab is a "highly effective treatment which potentially improves the outcomes of patients with classical Hodgkin lymphoma worldwide."

Sintilimab was approved for market authorization by China's National Medical Products Administration in December 2018.

"The approval will bring more treatment options for cancer patients in China," Shi said. 

   Print   To Top    Close  
0

Related Articles

AI association to draft ethics guidelines
World looks East as China gives new impetus to science, tech development
China the only place to do it, says BYTON president
UCAR, Borgward partner in auto retail-platform
China-Singapore airport management JV operational in Chongqing
Chinese scientists develop anticorrosion method for steel in marine engineering
China honors distinguished scientists
Tesla breaks ground on gigafactory in Shanghai
Ancient tombs discovered underneath a planned university canteen in China
Blinking may indicate attention levels
   
Home  │ About Liuzhou  │ Site Map  │ Service and Privacy │ FAQ │ Download Forms   │ Contact Us
Copyright (C) 2006 The People's Government of Liuzhou Municipality,All Rights Reserved
Sponsored by Liuzhou Informational Leading Group Office (The Bureau Of The Information Industry Of Liuzhou)
Prepared by Liuzhou Network Management Centre Address:No. 66, Sanzhong Road, Liuzhou, China
ICP Certificate No.05009280